This presentation summarizes key clinical and anatomic outcomes from the phase 3 TENAYA/LUCERNE trials of faricimab▼ in treatment naive patients with nAMD are summarized, supporting comprehensive disease control and extended durability through dual Ang-2/VEGF-A pathway inhibition with faricimab▼. Various retinal biomarkers (CST, retinal fluid and PED) demonstrated greater improvements with faricimab▼ vs aflibercept.
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.
Not a healthcare professional? Browse:
This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.